Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19

In this randomized trial, adults who had been exposed to a household contact with Covid-19 were given nirmatrelvir–ritonavir or placebo. Prophylaxis with nirmatrelvir–ritonavir did not prevent symptomatic Covid-19.

​   The New England Journal of Medicine: Search Results in Infectious Disease